AstraZeneca's IL-33-targeting antibody tozorakimab has made the grade in two phase 3 chronic obstructive pulmonary disease (COPD) trials, raising the prospects of a class that has recorded some ...

Verschillende goede voorbeelden met aantoonbare impact vormen de basis voor de afspraken over de doorbraakmiddelen.

Met een nieuwe app screenen COPD patiënten zich thuis op atriumfibrilleren, wat vroege opsporing van atriumfibrilleren bij ...

Hoeveel bestrijdingsmiddelen krijgen kinderen eigenlijk binnen via hun leefomgeving en voedsel? En: wat voor effect heeft dat ...

Conclusion People living with COPD are at a significantly heightened risk of CVD over and beyond their predicted risk. This is particularly the case for younger people whose 10-year CVD risk can be ...

There are over 16 million people in America diagnosed with COPD however millions more are living with COPD but do not know it, yet. There is no cure for COPD, which includes emphysema and chronic ...

COPD treft wereldwijd bijna 400 miljoen mensen en is de derde doodsoorzaak ter wereld. Meer dan 50% van de patiënten die de inhalatiestandaard gebruiken, ervaart exacerbaties, die het risico op ...

Rival treatments had mixed results in the past AstraZeneca sees $3-5 billion peak annual sales for its drug Detailed results to be presented at upcoming medical conference Shares among biggest gainers ...

AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has hit the mark in a pair of phase 3 trials, delivering broad efficacy with a mechanism that yielded mixed data for Roche and ...

Clinical benefits of the interleukin-33 inhibitor were observed in a broad population, including both former and current smokers, regardless of eosinophil levels. Topline results were announced from ...

AstraZeneca’s IL-33 blocker, tozorakimab has significantly reduced the annualised rate of COPD exacerbations as an adjuvant to SoC inhaled therapy over placebo in two Phase III studies. Credit: ...

AstraZeneca didn’t release complete data from the trials, called Oberon and Titania, stating that they will be disclosed at an upcoming medical meeting. Those details will be closely watched.